Australian researchers said that the salicylate drug, aspirin and other household drugs may slow down or restrain the increase of cancer because they help shut down the chemical highways which nourish tumors.

On Tuesday, researchers from a major center for cancer treatment, Peter MacCallum Cancer Centre, Melbourne said that they have made a biological step forward helping describe how lymphatic vessels are important to the transmission of tumors all over the body to respond to cancer.

Researcher Steven Stacker said that they have shown that molecules like aspirin could well work by reducing the dilation of these main vessels and thus reducing the ability of tumors to increase to isolated sites.

By studying cells in lymphatic vessels, Peter MacCallum Cancer Centre researcher found that a particular gene changed its appearance in cancers which spread.

The study of the researchers published in scientific journal “Cancer Cell” showed that the gene is a relation between a tumor’s growth and the cellular way which can be the reason for inflammation and dilation of vessels all over the body.

The study showed that once these lymphatic vessels expand, the competence for them to operate as supply lines to tumors and become more useful conduits for the cancer to widen is augmented, however aspirin acts to shut down the dilation of the vessels.

Stacker said that it seems like they have found an essential connection point in a biochemical sense between all these different contributors.

The researchers said that this latest discovery could lead to novel and better drugs which could help contain many solid tumors, as well as potentially provide an early warning system before a tumor starts to increase.

*************************************************************

The Views and Opinions expressed by the author are his or her opinions only and do not necessarily reflect those of this Web-Site or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company or person mentioned or referred to in the article.